CLINICAL TRIALS PROFILE FOR EMODEPSIDE

Clinical Trials for Emodepside

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02661178 ↗	First in Man Clinical Trial of Emodepside (BAY 44-4400)	Completed	Bayer	Phase 1	This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers. This study will also conduct an exploratory investigation of the relative bioavailability of emodepside administered as tablets and determine the effect of food on the pharmacokinetics.
NCT02661178 ↗	First in Man Clinical Trial of Emodepside (BAY 44-4400)	Completed	Bill and Melinda Gates Foundation	Phase 1	This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers. This study will also conduct an exploratory investigation of the relative bioavailability of emodepside administered as tablets and determine the effect of food on the pharmacokinetics.
NCT02661178 ↗	First in Man Clinical Trial of Emodepside (BAY 44-4400)	Completed	Drugs for Neglected Diseases	Phase 1	This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers. This study will also conduct an exploratory investigation of the relative bioavailability of emodepside administered as tablets and determine the effect of food on the pharmacokinetics.
NCT03383523 ↗	Relative Bioavailability Study of Emodepside IR-tablets and Solution	Completed	Bayer	Phase 1	This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov identifier: NCT02661178)
NCT03383523 ↗	Relative Bioavailability Study of Emodepside IR-tablets and Solution	Completed	Bill and Melinda Gates Foundation	Phase 1	This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov identifier: NCT02661178)

Clinical Trial Conditions for Emodepside

Condition Name

Condition Name for
Intervention	Trials
Filariasis	2
Hookworm Infections	2
Trichuris Trichiura; Infection	1
Healthy Volunteers	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Ancylostomiasis	2
Filariasis	2
Hookworm Infections	2
Onchocerciasis	1

Clinical Trial Locations for Emodepside

Trials by Country

Trials by Country for
Location	Trials
United Kingdom	3
Tanzania	2
Ghana	1

Clinical Trial Progress for Emodepside

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	3
Phase 1	3

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	3
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for Emodepside

Sponsor Name

Sponsor Name for
Sponsor	Trials
Bayer	4
Drugs for Neglected Diseases	4
Bill and Melinda Gates Foundation	3

Sponsor Type

Sponsor Type for
Sponsor	Trials
Other	11
Industry	4